ReviewFrontiers in immunology2020
The Immunological Basis of Liver Allograft Rejection.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Navigating the risks: a systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes.Frontiers in oncology · 2025Pooled it
- Analytical and Clinical Validation of a Serum microRNA RT-qPCR Assay for Detection of Acute Cellular Rejection in Liver Transplant Recipients.Diagnostics (Basel, Switzerland) · 2026Article
- Liver Tissueoid on-a-Chip Modeling Liver Regeneration and Allograft Rejection.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Observational
- Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions.Clinical and experimental medicine · 2026Review
- Unique Immune Polarization of the Lung Allograft: Implications for Organ-specific Immunoregulation and Tolerance Induction.Transplantation · 2026Review
- Evaluating diagnosis and clinical outcome for antibody-mediated rejection in liver transplantation: performance of the 2016 Banff Working Group criteria.Virchows Archiv : an international journal of pathology · 2026Article
- Single-cell and spatial transcriptomics reveal transplant-associated T cells and myeloid cells in human liver transplantation.Frontiers in immunology · 2026Article
- Immunopathogenesis of antibody-mediated rejection in liver transplantation.Frontiers in immunology · 2026Review
- Nanomedicine in Organ Transplantation: From Graft Preservation and Repair to Immunomodulation and Monitoring.Theranostics · 2026Review
- Artificially Engineered Synthetic Biomarkers Revolutionizing Early Diagnosis of Diseases.Molecules (Basel, Switzerland) · 2025Review
- Article
- Assessment of Donor-Specific Human Leukocyte Antigen Antibodies Following Pediatric Liver Transplantation: Predictors, Protectors, and Clinical Relevance.Clinical transplantation · 2025Article
- Review
- Associations Between Pre-Transplantation T Cell Populations and Acute Cellular Rejection Post-Liver Transplantation-Results From a Prospective Cohort Study.Scandinavian journal of immunology · 2025Article
- Understanding Immune Dynamics in Liver Transplant Through Mathematical Modeling.Bulletin of mathematical biology · 2025Article
- Donor liver natural killer cells ameliorate liver allograft rejection via inducing apoptosis of alloreactive CD8Scientific reports · 2025Article
- Ginkgolic acid inhibits CD8Journal of pharmaceutical analysis · 2025Article
- Annexin A1-FPR1 Interaction in dendritic cells promotes immune microenvironment modulation in Thyroid Cancer.Cell biology and toxicology · 2025Article
- Diagnostic and predictive biomarkers of acute rejection after liver transplantation.International journal of surgery (London, England) · 2025Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver allograft rejection remains a significant cause of morbidity and graft failure in liver transplant recipients. Rejection is caused by the recognition of non-self donor alloantigens by recipient T-cells. Antigen recognition results in proliferation and activation of T-cells in lymphoid tissue before migration to the allograft. Activated T-cells have a variety of effector mechanisms including direct T-cell mediated damage to bile ducts, endothelium and hepatocytes and indirect effects through cytokine production and recruitment of tissue-destructive inflammatory cells. These effects explain the histological appearances of typical acute T-cell mediated rejection. In addition, donor specific antibodies, most typically against HLA antigens, may give rise to antibody-mediated rejection causing damage to the allograft primarily through endothelial injury. However, as an immune-privileged site there are several mechanisms in the liver capable of overcoming rejection and promoting tolerance to the graft, particularly in the context of recruitment of regulatory T-cells and promotors of an immunosuppressive environment. Indeed, around 20% of transplant recipients can be successfully weaned from immunosuppression. Hence, the host immunological response to the liver allograft is best regarded as a balance between rejection-promoting and tolerance-promoting factors. Understanding this balance provides insight into potential mechanisms for novel anti-rejection therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.